Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)

4.03
BATS BZX Real-Time Price
As of 9:51am ET
 +0.18 / +4.68%
Today’s Change
2.40
Today|||52-Week Range
5.88
+4.68%
Year-to-Date
AcelRx (ACRX) Initiates Phase III IAP312 Study on Zalviso
9:32am / Zacks.com - Paid Partner Content
Company News for September 16, 2016
Sep 16 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close3.85
Today’s open3.94
Day’s range3.67 - 4.06
Volume2,834
Average volume (3 months)368,598
Market cap$174.5M
Dividend yield--
Data as of 9:51am ET, 09/28/2016

Growth & Valuation

Earnings growth (last year)+34.07%
Earnings growth (this year)-49.67%
Earnings growth (next 5 years)+46.60%
Revenue growth (last year)+269.24%
P/E ratioNM
Price/Sales8.89
Price/Book5.26

Competitors

 Today’s
change
Today’s
% change
PRQRProQR Therapeutics N...+0.29+3.85%
DPRXDipexium Pharmaceuti...+0.50+3.03%
OCULOcular Therapeutix I...+0.08+1.16%
MDWDMediwound Ltd0.000.00%
Data as of 9:50am ET, 09/28/2016

Financials

Next reporting dateNovember 1, 2016
EPS forecast (this quarter)-$0.24
Annual revenue (last year)$19.3M
Annual profit (last year)-$24.4M
Net profit margin-126.66%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Director
Howard B. Rosen
CFO &
Head-Business Development
Timothy E. Morris
Corporate headquarters
Redwood City, California

Forecasts

Search for Jobs